Oath Research Transparency Rating: Public COA Archive Scored

What drives the transparency rating

The Oath Research transparency rating lands at 85 of 100 because the public COA archive does three things at once that most vendors do one of at best — and gives one of them back at the gate.

First, it is partly public. 250 of the 425 certificates on file in August 2026 are searchable without an account; the other 175 require a login. Anyone with a browser and a batch number can pull most certificates without creating one — but not all of them, and that is the single largest deduction in this category. An archive whose access criterion is named 'public access' does not earn full marks while two-fifths of it sits behind a sign-in wall, so the criterion takes 15 of 25 rather than the 25 it held when the whole archive was open.

Second, it is multi-axis searchable. The same archive can be queried by peptide name, by batch number, or by CAS number. Three independent retrieval paths matter because a customer who knows only one of those values can still verify a lot — and because three independent indices are harder to fake at scale than one curated front page.

Third, it is lab-attributed. Every COA names Freedom Diagnostics as the issuing laboratory, not 'a third-party lab' generically. Naming the lab makes the chain externally checkable, and RealPeptidesScores' Grade A audit explicitly verified Freedom Diagnostics as the named lab partner at scrape time.

What is Oath Research's transparency score?

85 of 100 — high band. Four of six criteria capture full points (search depth 20/20, per-COA detail 20/20, archive scope 15/15, recency 10/10). The other two carry the deductions. COA public access scores 15/25: 250 of the 425 certificates on file in August 2026 open without an account and the remaining 175 require a login, so roughly three-fifths of the archive is openly accessible and the criterion earns proportionate rather than full credit. Third-party listing parity scores 5/10, reflecting that RealPeptidesScores' independent audit captured 142 COAs, a partial view relative to the company's own current archive — not a transparency knock against the company. The transparency rating carries 25% weight in the overall rubric because public verifiability is what converts a testing claim into an auditable record.

Does Oath Research publish COAs?

Yes. COAs are publicly searchable on oathresearch.com by peptide name, batch number, or CAS number — 250 of the 425 certificates on file in August 2026 are viewable without an account, and the rest require a login. Each COA shows purity %, test date, and the named issuing laboratory (Freedom Diagnostics). This three-axis searchability is the central transparency mechanism behind the transparency rating's top-tier score.

How recent are Oath Research's lab tests?

Tests dated as recently as August 2026 appear in the public COA archive. A 2026-05-26 research snapshot found tests across multiple peptides (SS-31, BPC-157, GLP2-T tirzepatide, Selank, Tesamorelin+Ipamorelin, WOLVERINE blend), and RealPeptidesScores' independent audit (9 May 2026) confirmed 109 of 142 captured COAs fell within the last 90 days of that audit — a cadence of roughly 36.3 COAs per month at that time. Test recency demonstrates an actively maintained testing program, not a one-time launch artifact, and captures the full 10 points allocated to the recency criterion.

Can I trust Oath Research's COAs?

Three structural properties make the record verifiable rather than self-asserted. First, the COAs originate from Freedom Diagnostics, an independent third-party laboratory — not an in-house or affiliated function. Second, the archive is batch-level rather than lot-level or spot-check, with 1:1 batch-to-COA parity (one certificate per tested batch). Third, the archive is publicly indexed by three independent axes (peptide name, batch number, CAS number), making the chain queryable from whichever data point the reader holds.

The strongest available signal is customer-side independent verification. At least one customer (Nancy I., amino.reviews / oath.reviews, 23 May 2026) reports having sent a sample of Oath's tirzepatide to an independent third-party laboratory for retest and confirmed the results lined up with the posted COA. A customer running their own external retest and corroborating the published certificate is verification at a higher tier than reviewer attestation. RealPeptidesScores' independent audit is a second corroboration.

Is Oath Research listed on RealPeptidesScores?

Yes. RealPeptidesScores rates Oath Research at Grade A — Recommended, with the lab partner independently verified as Freedom Diagnostics. The audit summary characterizes Oath as 'per-batch, portal-verifiable, and four times the cadence of anyone else we audited.' The RPS listing, dated 9 May 2026, displayed 142 of the batches Oath publishes at that time — the company's own COA archive remains the more complete, current record.

Where the fifteen points went

The 15-point deduction in the transparency category sits in two criteria.

COA public access — 15 of 25. The archive was fully open when this rating was first written. It is not now: the certificate index reports 250 of 425 on file in August 2026 as viewable, with the remainder available only after creating an account. The login is free, which is why the value category still scores COA verification cost at full points — but this criterion measures access, not price, and an access criterion cannot return full marks while two-fifths of the record is gated. Scoring it in proportion to the openly readable share puts it at 15 of 25. If the archive reopens in full, the criterion returns to 25.

Third-party listing parity — 5 of 10. RealPeptidesScores' independent audit captured 142 COAs — a partial view relative to the company's current archive, which has continued to grow. The rubric scores this criterion on the assumption that at least most of the company's archive is independently displayed by a disclosed-methodology third party; on the evidence available, Oath's listing is a partial fulfillment, not a missing one. A future RPS re-audit that catches up to the company's current archive would lift this criterion to full points.